Top Markets
#1 Strategic Oil Supply Strategic Oil Supply +124.78%
#2 Win Win +87.71%
#3 Anvil Anvil +57.82%
#4 Switch Token Switch Token +40.05%
#5 City Boy City Boy +33.14%
#6 Freedom of Money Freedom of Money +25.48%
#7 Siren Siren +24.63%
#8 Electroneum Electroneum +24.43%
#9 Infinity Ground Infinity Ground +18.16%
#10 Bityuan Bityuan +15.58%
Coin of the day
Strategic Oil Supply Strategic Oil Supply
Settings
Language
ENGLISH
Currency
USD
Theme
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rank in Stocks #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Share Price
$451.59
Market Cap
$114.70B
Change (1 day)
-2.36%
Change (1 year)
-11.84%
Country
US
Trade Vertex Pharmaceuticals Incorporated (VRTX)

Category

Healthcare
Earnings for Vertex Pharmaceuticals Incorporated (VRTX)
Earnings in Dec 2025 TTM: $4.64B
According to Vertex Pharmaceuticals Incorporated latest financial reports the company's current earnings are $4.64B. In 2024 the company made an earning of $248.50M, a decrease compared to its 2023 earnings that were of $4.38B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Vertex Pharmaceuticals Incorporated from 2000 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $4.64B 0.00%
2025 $4.64B 1,768.49%
2024 $248.50M -94.33%
2023 $4.38B 3.48%
2022 $4.23B 55.01%
2021 $2.73B -12.40%
2020 $3.12B 123.45%
2019 $1.39B 132.39%
2018 $600.24M -3,925.87%
2017 $-15.69M -76.71%
2016 $-67.37M -87.96%
2015 $-559.58M -23.85%
2014 $-734.88M -24.71%
2013 $-976.12M 7,783.99%
2012 $-12.38M -120.48%
2011 $60.45M -108.01%
2010 $-754.63M 17.51%
2009 $-642.18M 38.35%
2008 $-464.18M 8.73%
2007 $-426.91M 106.35%
2006 $-206.89M 19.32%
2005 $-173.39M 9.39%
2004 $-158.51M -54.37%
2003 $-347.35M 190.28%
2002 $-119.66M 1.50%
2001 $-117.89M 119.92%
2000 $-53.61M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B 340.58%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 12.65%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -53.96%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -65.23%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -68.75%
NL